Division of Infectious Diseases, Department of Internal Medicine, University of Iowa, Iowa City, Iowa 52242, USA; email:
Division of Pulmonary and Critical Care, Department of Internal Medicine, University of Iowa, Iowa City, Iowa 52242, USA; email:
Annu Rev Med. 2022 Jan 27;73:563-574. doi: 10.1146/annurev-med-042120-020148.
Cystic fibrosis (CF) is an autosomal recessive genetic disorder caused by mutations in , the cystic fibrosis transmembrane conductance regulator gene. People with CF experience a wide variety of medical conditions that affect the pulmonary, endocrine, gastrointestinal, pancreatic, biliary, and reproductive systems. Traditionally, CF carriers, with one defective copy of , were not thought to be at risk for CF-associated diseases. However, an emerging body of literature suggests that heterozygotes are at increased risk for many of the same conditions as homozygotes. For example, heterozygotes appear to be at increased risk for chronic pancreatitis, atypical mycobacterial infections, and bronchiectasis. In the United States alone, there are almost 10 million CF carriers. Universal newborn screening and prenatal genetic screening will identify more. Thus, there is a critical need to develop more precise estimates of health risks attributable to the CF carrier state across the lifespan.
囊性纤维化(CF)是一种常染色体隐性遗传疾病,由囊性纤维化跨膜电导调节基因中的突变引起。CF 患者会经历多种影响肺部、内分泌、胃肠道、胰腺、胆道和生殖系统的疾病。传统上,携带一个缺陷拷贝的 CF 携带者被认为不会有 CF 相关疾病的风险。然而,越来越多的文献表明,杂合子与纯合子一样,患许多相同疾病的风险增加。例如,杂合子似乎患慢性胰腺炎、非典型分枝杆菌感染和支气管扩张的风险增加。仅在美国,就有近 1000 万 CF 携带者。普遍的新生儿筛查和产前基因筛查将发现更多的携带者。因此,迫切需要在整个生命周期内对 CF 携带者状态导致的健康风险进行更精确的估计。